Cite

    Murayama, H. et al. (2019). Relationship of patient background with macro- and microvascular complications: a 2-year post-marketing surveillance of vildagliptin in nearly 20, 000 Japanese diabetic patients. Expert opinion on pharmacotherapy. pp. 1037-1047. [Online].